In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the world's leading drugmakers, missed last ...

Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

In a release, Vertex said the medicine will be sold as a 50-milligram prescription pill taken every 12 hours and will cost $15.50 per pill. The FDA said the drug was tested in two trials with more ...

Vertex is now the first drugmaker in decades to gain U.S. approval for a new type of pain medicine. It's a milestone after a long history of mostly unsuccessful efforts to develop painkillers ...

They will if the generic drug is an opioid that carries the potential for addiction and the new medicine is a non-opioid that poses no such known risk. That’s the opinion of top Vertex ...

With the U.S. still mired in an overdose crisis that’s killed hundreds of thousands of people, Vertex is positioning its medicine as a valuable alternative to opioid-based therapies. Doctors say ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...